This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Enthera S.r.l.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Giovanni Amabile: Innovator in Antibody Therapeutics
Introduction
Giovanni Amabile is a prominent inventor based in Milan, Italy. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on innovative solutions that address critical health challenges.
Latest Patents
Giovanni Amabile holds a patent for "TMEM219 antibodies and therapeutic uses thereof." This invention relates to antibodies or antigen-binding fragments that specifically bind to the IGFBP3 receptor, namely TMEM219. The patent outlines methods for their production, pharmaceutical compositions containing these antibodies, and their various therapeutic uses. He has 1 patent to his name.
Career Highlights
Amabile is currently associated with Enthera S.r.l., a company dedicated to advancing therapeutic solutions in the biotechnology sector. His role at Enthera allows him to leverage his expertise in antibody development to create impactful medical treatments.
Collaborations
Throughout his career, Giovanni has collaborated with notable professionals in the field, including Paolo Fiorina and Francesca D'Addio. These partnerships have enhanced his research and contributed to the advancement of innovative therapeutic approaches.
Conclusion
Giovanni Amabile is a key figure in the development of antibody therapeutics, with a focus on TMEM219. His contributions to the field are significant, and his ongoing work at Enthera S.r.l. continues to push the boundaries of biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile